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Abstract
Background: Clinical management of malaria is a major health issue in sub-Saharan Africa. New strategies based on
intermittent preventive treatment (IPT) can tackle disease burden by simultaneously reducing frequency of infections and
life-threatening illness in infants (IPTi) and children (IPTc), while allowing for immunity to build up. However, concerns as to
whether immunity develops efficiently in treated individuals, and whether there is a rebound effect after treatment is
halted, have made it imperative to define the effects that IPTi and IPTc exert on the clinical malaria scenario.
Methods and Findings: Here, we simulate several schemes of intervention under different transmission settings, while
varying immunity build up assumptions. Our model predicts that infection risk and effectiveness of acquisition of clinical
immunity under prophylactic effect are associated to intervention impact during treatment and follow-up periods. These
effects vary across regions of different endemicity and are highly correlated with the interplay between the timing of
interventions in age and the age dependent risk of acquiring an infection. However, even when significant rebound effects
are predicted to occur, the overall intervention impact is positive.
Conclusions: IPTi is predicted to have minimal impact on the acquisition of clinical immunity, since it does not interfere with
the occurrence of mild infections, thus failing to reduce the underlying force of infection. On the contrary, IPTc has a
significant potential to reduce transmission, specifically in areas where it is already low to moderate.
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Introduction
Malaria exerts a huge morbidity and mortality toll on people in
sub-Saharan Africa [1,2]. This heavy burden raises the need to
optimise control tools and devise appropriate intervention
schemes. Several trials have tried to reduce the risk of acquisition
of life threatening malaria infections through the use of
prophylaxis [3–5]. In endemic settings, prophylaxis has been
shown to protect children from episodes of malaria, anaemia and
death [6]. Despite its beneficial impact, mass implementation of
chemoprophylaxis raises concerns that need to be taken into
serious consideration: (1) whether immunity in treated individuals
develops as in untreated ones (whether there is a rebound effect);
(2) spread of drug resistance; (3) costs; (4) logistic complexity.
New strategies designed to deal with such potential drawbacks
have been put forward and into practice. Particularly, the
administration of anti-malarial drugs to pregnant women through
intermittent preventive treatment (IPTp), has been quite successful
at protecting them from malaria and placental parasitaemia, and
their newborns from malaria-associated low birth weight [7,8].
Results encouraged the idealisation of new strategies that could
revolutionise clinical management of malaria, by effectively
targeting at-risk patients in endemic areas. Since in endemic areas
incidence of clinical malaria is higher in young children [9–11]
and pregnant women [12], the IPT strategy was later on expanded
to infants [13–16] and children [17–19]. Intermittent preventive
treatment consists of the administration of a therapeutic course of
an anti-malarial drug at predetermined intervals, regardless of
infection status [20,21]. The purpose is to clear any current
infection and prevent new ones. The intervals between doses are
longer than the time to clear the drug from the bloodstream
(although this would depend on the type of drug used), ideally
allowing for infections between doses. The ultimate goal is, then,
to simultaneously reduce frequency of infection and life-threaten-
ing illness, while allowing immunity to build up.
Because fewer doses are given compared to chemoprophylaxis,
concerns about cost and drug resistance are significantly reduced.
We will not dwell on how IPT might alter emergence and spread of
drug resistance,as ithasbeen studied elsewhere[22,23]. Whereasin
infants (IPTi) delivery is made during the routine vaccinations of the
Expanded Programme on Immunization (EPI), for IPT in children
(IPTc) drug delivery is not supported by any existing public health
program,butratherreliesoncommunityvolunteers.Nevertheless,a
pilot study conducted in Senegal achieved over 80% IPTc coverage
while using community volunteers for drug deployment [24], which
attests the logistic feasibility of such an intervention.
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tions for the unsettled question of whether immunity in treated
individuals develops as in untreated ones, and a precise evaluation
of IPT interventions efficacy in different endemic settings is
required. It is important to define as clearly as possible the
conditions under which the current conception of IPTi within the
EPI delivery system, and IPTc administered to a specific age range
of children, according to a particular schedule will be beneficial.
We will explore the possible scenarios by simulating different
schemes of intervention and transmission settings, relying on
empirical data [15,19] for model calibration.
The establishment of whether (and if so under which conditions)
a rebound effect is observed is of major importance to advise
control programmes being implemented in the field. So far,
reports on outcomes of IPTi interventions have been inconclusive
and contradictory to some extent. Whereas all studies show a great
decrease (at least 20%) in the number of clinical cases during the
treatment period [13–16], there is a noticeable disparity regarding
follow up period results. Some studies report extended protection
after treatment [15], while others claim an increase in clinical cases
[13,14], even as high as 100% more cases of severe malaria in the
treated group [14]. Previous modelling work has predicted IPTi
efficacy to be higher where IPTi coverage is greater, the health
system treatment coverage lower, and for more efficacious and
longer lasting drugs [25]. Also, IPTi impact on transmission
intensity was estimated to be negligible [25]. The two models
developed so far have suggested that there is increased
susceptibility between doses and following the last dose, although
these effects are outweighed by the overall intervention benefits
[25,26].
For IPTc, the scarce data that exists refers to studies conducted
in seasonal transmission settings, in which reported efficacy
reached as much as 90% [17–19]. No long term follow up data
are available at the moment. An important question is then to
assess the optimal timing for the administration of drug courses in
areas where malaria transmission is highly seasonal.
Methods
Transmission model
We built a simple model to simulate IPT interventions in a
given cohort. Overlaid on a basic topology describing the
transmission of malaria in a given population [27], we apply an
intervention strategy consisting of giving a varying number of
therapeutic courses of an anti-malarial drug. The model is
represented by the system of differential equations:
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where each variable represents the proportion of the population at
any given age and time in eight epidemiological states: completely
susceptible untreated (S) and treated (ST); clinical malaria resulting
from infection in a completely susceptible untreated (I1) or treated
individual (I1T); recovered with clinical natural immunity (R)o r
immunity acquired while treated (RT); and mild or asymptomatic
infection resulting from exposure of recovered untreated (I2)o r
treated individuals (I2T). The force of infection is an age-dependent
function defined previously in [27] as:
l a ðÞ ~l0 1{re{ka   
: ð2Þ
The function is strictly increasing with age, with a minimum
l0(12r) (at age zero) converging asymptotically to l0 as age
increases. Parameter k determines how steeply the force of
infection increases with age, and r controls the magnitude of that
increase.
A summary measure of transmission is obtained by integrating
the force of infection over age as:
L~
ð
l a ðÞ Pa ðÞ da ð3Þ
where Pa ðÞ ~me{ma is the total population distributed over age
and m is the birth and death rate. One must bear in mind that this
formulation is generic and should be adjusted for specific
populations by using real population age profiles.
Adopting standard assumptions, L is proportional to the
frequency of infectious individuals, the proportionality constant
being the transmission coefficient,
b~L= I1zI2zI1TzI2T ðÞ ð 4Þ
The force of infection can be seasonally forced by making b a
time dependent variable. Adapting a standard sinusoidal function:
b t ðÞ ~b0z b0dcos 2p t{w ðÞ ðÞ ðÞ ð 5Þ
where b0 is the baseline transmission coefficient, and d is the
amplitude, and w the phase of the variation.
The boundary conditions for system (1) at age a=0 are
St ,0 ðÞ ~m and Rt ,0 ðÞ ~I1 t,0 ðÞ ~I2 t,0 ðÞ ~ST t,0 ðÞ ~RT t,0 ðÞ ~
I1T t,0 ðÞ ~I2T t,0 ðÞ . We used the escalator boxcar train (EBT)
technique to model the dynamics in our age structured population.
This is a numerical method used for physiologically structured
population models [28].
The transmission parameter values for the non-treated classes
were estimated from datasets from 8 regions in sub-Saharan Africa
[27]. Treatment moves a proportion of individuals of each class,
determined by the intervention programme coverage, c, to the
corresponding treated class, represented by subscript T. The
dynamics of transmission in the treated compartments mimics that
of the basic model, but is governed by different parameters
representing the prophylactic effect of anti-malarial drugs, which
wanes at a rate ac. Rates of drug clearance and recovery from
infection for the treated classes are taken from the literature [29–
31]. Immunity in the treated classes also wanes, but not much is
known about the dynamics of clinical protection loss. We have,
thus, equalled it to the loss of immunity in the untreated classes.
We introduce a parameter c to represent the proportion of clinical
IPT Impact on Clinical Malaria
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also introduce a parameter s to account for the reduction in the
risk of acquiring a new infection while treated.
The model dynamics are schematically represented in Figure 1
and the model parameters defined in Table 1.
Modelling IPTi
To assert the benefits of intervening on a given endemic
population, we first simulate our age structured model in
equilibrium conditions to obtain the age profile of clinical disease
prevalence without any intervention. We use that age profile as the
initial condition for the simulation in which IPTi is implemented.
We assume EPI coverage of 90% in concordance with the
guidelines for the EPI initiative [32], and simulate a scenario of
intervention at ages 2, 3 and 9 months for 10 years. We assumed
that a percentage (g) of clinical malaria infections is undergoing first
line drug treatment. We consider that 13% of clinical cases are
severe [33] and that 50% of those receive appropriate first line
treatment [25]. The remaining non-severe clinical malaria cases are
assumed to be treated with a 20% probability [25]. The individuals
undergoing first line treatment are precluded from receiving any
IPTi dose. Intervention works by, at each instant in time, moving
individuals in untreated classes of cohorts that have just entered an
age class corresponding to any age of intervention, to the
corresponding treated classes, according to their respective IPT
coverage rate.Interventionoutcome is measuredintermsofimpact,
defined as the percentage reductionininfectionor disease causedby
an intervention in a trial group (simulated intervention) compared
to a control group (simulation without any intervention).
Modelling IPTc
Simulation of IPTc interventions is similar to that of IPTi,
except intervention is not continuous in time, but rather for a
specific age range. Specifically, interventions occur at predeter-
mined instances over a 1 year period, targeting a given age range.
We decided to mimic one study conducted in primary schools in
Kenya, in which children aged 5–18 years received 3 doses of anti-
malarial drugs at 4 months intervals [19], since this is the study
that comprised the largest number of people, with the largest age
span, over the greatest period of time. We consider these study
characteristics as ideal premises to compare our model with data
and test the dynamics between pulses of drug administration, as
well as the long term impact of IPTc. We expanded our analysis to
a second study which focuses on the administration of IPTc
targeting the high transmission season, in a markedly seasonal
setting [34]. Here, children aged 2 months to 5 years of age receive
a monthly course of drugs, for 3 months. This is an ideal setup to
investigate the importance of seasonality and drug administration
timing on intervention outcome.
Implementing seasonality
The general time dependent transmission function was adjusted
to the two settings simulated here [19,34]. Whereas in the Kenyan
study site transmission is intense and perennial, with two seasonal
Table 1. Model parameters.
Parameter Definition Value
m Birth and death rate 1/50 yrs
21
t1 Rate of recovery from I1 infections 14.12 yrs
21
t2 Rate of recovery from I2 infections 2.23 yrs
21
a Rate of loss of acquired immunity in R 1.07 yrs
21
c Prophylaxis coverage 0.9
g First line drug treatment coverage 0.24
ac Clearance rate of the drugs from the bloodstream 12 yrs
21
at Loss of immunity acquired while treated 1.07 yrs
21
s Reduced risk of infection while treated Variable
c Probability of clinical immunity acquisition Variable
e1 Recovery rate from I1T infections 120 yrs
21
e1 Recovery rate from I2T infections 120 yrs
21
b Transmission coefficient Variable
w Phase of seasonal fluctuations Variable
d Amplitude of seasonal fluctuations 0.5
l(a) Age dependent force of infection Variable
doi:10.1371/journal.pone.0006627.t001
Figure 1. Model representing the dynamics of malaria trans-
mission in a population under treatment. The model is an
extension of the model in [27]. The compartments represent the
following epidemiological classes: S=completely susceptible individu-
als, either newborns, or individuals that have lost protection conferred
in R, or have cleared drugs from the bloodstream while in ST; I1=clinical
malaria resulting from an infection in a completely susceptible
individual or after drug clearance from I1T; R=individuals that recovered
from infections I1 or I2 or that have cleared the drugs from circulation
while in RT, and are clinically immune, developing a mild form of disease
if exposed. I2=mild/asymptomatic disease resulting from exposure of
recovered individuals or drug clearance while in I2T. ST=completely
susceptible individuals that were treated, have lost immunity conferred
in RT, or failed to build up their immunity after an infection. I1T=severe
disease resulting from an infection in a treated susceptible individual, or
treated while in I1. RT=individuals that recovered from infections I1T or
I2T and acquired clinical protection, or where treated while in R.
I2T=mild/asymptomatic disease resulting from exposure of RT individ-
uals or treated while in I2. The parameters are described in Table 1. A
percentage of infants (according to programme coverage) depicted as c
is discretely moved to the corresponding treated classes, at specific
ages.
doi:10.1371/journal.pone.0006627.g001
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Senegalese region there is a single high transmission season from
August to October [34]. The seasonal transmission coefficients for
the Kenyan site in study [19] (BK) and for the Senegalese site in
[39] (BS) were then defined as:
bK t ðÞ ~bK0z bK00:5cos 3:85p t{0:15 ðÞ ðÞ ðÞ ð 6Þ
bS t ðÞ ~bS0z bS00:5cos 2p t{0:67 ðÞ ðÞ ðÞ ð 7Þ
Results
We will present the results either in the form of age profiles
retrieved at specific points in time, or time plots, where each point
represents the integral of the corresponding age profile. We will
convey the malaria scenario in the simulated population as
proportions of clinical malaria and parasite prevalence. The
former is equal to the proportion of people with clinical malaria in
the overall population, in other words, the prevalence of clinical
malaria, while the later is the proportion of people infected with a
malaria parasite in the population, regardless of symptoms.
For the sake of simplicity we have established a nomenclature to
define the transmission levels associated to the simulations. The
most reliable measure of transmission on a given region is the
overall parasite prevalence registered at a given time. We have,
then, defined 3 classes of transmission according to parasite
prevalence. Henceforth, we will refer to as low transmission
settings, those regions where a cross-sectional survey would detect
parasites is less than 10% of the individuals. If that value is within
the 11–50% range, the region is defined as an intermediate
transmission setting, while parasite prevalence above 50% would
categorize the region as a high transmission setting.
IPTi
Figures 2A and 2C investigate how the probability of acquiring
clinical immunity when infected while in the ST class, c, and the
reduced risk of acquiring an infection while treated, s, modulate
the age profiles of clinical malaria. We show the age profiles for the
parameter combinations that result in the best (green line) and
worst (red line) intervention impacts, as well as a parameter
combination assuming an empirical estimate for s [35–37] and a
conservative guess for c (blue line). In Figure 2A, we use a value for
the force of infection corresponding to a high transmission setting
(in this case parasite prevalence if around 90%). We observe that,
if immunity is efficiently acquired upon clinical infection,c=1, and
the drug does not reduce the risk of having a malaria infection,
s~1 (green line), the predicted rebound effect is minimised. For
intermediate levels, c~s~0:5, of these parameters (blue line), the
model suggests that rebound becomes significant after the first year
of life. This effect is exacerbated when treatment prevents infection
from occurring and clinical immunity is not built up due to
prophylaxis, c~s~0 (red line). From the green, c~s~1, to the
red line, c~s~0, the proportion of cases predicted to be
prevented up to age 10 decreases from 12.8% to 0.9%, being
5.6% for the blue line, c~s~0:5 (Table 2). Generally, these
results suggest that there is an evident beneficial effect at the ages
targeted by treatment, regardless of parameter values. More
importantly, there is a noticeable rebound effect, meaning that the
treated group is at increased risk of having a clinical malaria
episode, after the last dose of treatment.
Figure 2C shows the simulated effectiveness of anti-malarial
drugs during treatment and follow-up periods, in an intermediate
transmission setting. The results described for Figure 2A are
maintained for lower transmission, except that both intervention
impact and rebound effect are at a smaller scale. This translates
into a prophylactic efficacy from ages 0 to 10 years old that range
from 1.04% to 1.6%, depending on the values for s and c (Table 3).
Figure 2B,D displays in greater detail how the simulated IPTi
protective efficacy changes over age, when c~s~0:5. The highest
protective effects are always at the ages at which prophylaxis is
administered, and this protection gradually declines as drug effect
wanes. The larger rebound effect is expected to happen during the
first trimester of the second year of life, although for higher values
of both s and c, a rebound might occur between the second and
third prophylactic treatments. The extent of the rebound period is
highly sensitive to the duration of drug effect.
In Figure 3 we analyse the impact of IPTi at a specific point of
the transmission spectrum, focusing on the importance of tailored
interventions. In these simulations we assumed that, while treated,
the risk of infection upon challenge, and the chance to build up
clinical immunity upon infection is 0.5. We present in red an IPTi
schedule concomitant with the EPI vaccination ages, and in blue
the simulated intervention scenario that resulted in higher impact
in terms of proportion of clinical cases prevented. The predicted
optimal schedule for a three-dose intervention over the first year of
life for this specific transmission setting is to give prophylactic
treatment at 3, 5 and 7 months of age. Whereas in intermediate
transmission areas, targeted interventions seem to harness little
benefit (not shown), in high transmission regions a tailored
schedule may be responsible for the prevention of 8.3% of cases of
clinical malaria over all age classes, which contrasts with the 5.6%
obtained under the EPI schedule.
Figure 4A illustrates how program coverage is a critical
determinant of intervention outcome. Detailed analysis revealed
that the higher the proportion of the population under treatment,
the better the overall intervention impact is (Table 4). Despite
there being a higher rebound effect for higher IPTi coverage, the
largely lowered burden exerted on the first year of age renders
these interventions more effective against clinical malaria. High
coverage also achieves better impact on parasite prevalence,
although the actual reduction in the proportion of infectious
people is minimal (Figure 4B). These results have been proposed
by other modelling studies [25,26].
IPTc
IPTc intervention significantly disturbs the age dependent risk
of acquiring a malaria infection, which can be translated into age
profiles of clinical episodes as those in Figures 5–7.
In Figure 5A,C, we replicate the IPTc study carried out in in
western Kenya, by Clarke et al. [19]. We use the same
intervention schedule and a force of infection that reproduces
the observed pre-intervention parasite prevalence (close to 40%).
The model was able to reproduce this study’s results in terms of
the effect on the parasite prevalence (PP) in children aged 5 to 18
years. The study reports 89% (73%–95%) reduction in PP, while
we obtain impacts ranging from 81.2% to 84.9% depending on
the values for c and s. IPTc can be extremely efficient in lowering
the burden of clinical malaria in children (blue line in panel A),
albeit at the cost of a rebound effect just after a few months (red
line in panel A). The implementation of the same intervention in
high transmission regions (parasite prevalence above 80%)
(Figure 5B,D), indicates much lower efficacy in protecting against
clinical episodes (blue line in panel B), but significant rebound in
the age range under treatment (red line in panel B).
IPT Impact on Clinical Malaria
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6627Figure 2. IPTi impact on clinical malaria age profiles. Analysis of the outcome of applying prophylactics at 2, 3 and 9 months of age, for 10
years, in terms of age profile of clinical disease prevalence and intervention efficacy. Age profiles of populations under IPTi are compared with
populations without intervention, in equilibrium conditions (black line). (A) Simulations assuming different combinations of values for c and s, under
intense malaria transmission. The values for these 2 parameters are equal for each curve, ranging from c~s~1 (green line) to c~s~0 (red line). The
blue line represents the intermediate combination, c~s~0:5. (B) The dashed line represents the age instantaneous intervention efficacy for the blue
curve scenario in (A). The grey bars illustrate efficacy over a 3 months range. (C) Represents the same as in (A), but for a intermediate transmission
setting. (D) The dashed line represents the age instantaneous intervention efficacy for the blue curve scenario in (C). The grey bars illustrate efficacy
over a 3 months period.
doi:10.1371/journal.pone.0006627.g002
Table 2. Intervention impact below 10 years of age, for different values of c and s, under high transmission.
c Probability of clinical immunity acquisition
0 0.25 0.5 0.75 1
s Reduced risk of infection 1 0.0091 0.0458 0.0773 0.1046 0.1285
0.75 0.0090 0.0397 0.0669 0.0911 0.1128
0.5 0.0090 0.0334 0.0557 0.0762 0.0951
0.25 0.0089 0.0267 0.0435 0.0595 0.0747
0 0.0089 0.0196 0.0302 0.0407 0.0511
Impact is measured as the percentage reduction in malaria clinical cases caused by IPT in a trial group compared to a population without intervention.
doi:10.1371/journal.pone.0006627.t002
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profiles is shown in the video S1 while Figure 5 shows selected
profiles in age and time. In Figure 5A,B, we plot the simulated age
profile of a population where all children between the ages of 5
and 18 years have just received their third dose of prophylaxis
(blue line), and the corresponding age profiles four months after
that dose (red line) and previous to the start of intervention (black
line).
In Figure 5C,D, we visualize the time dynamics of both clinical
and asymptomatic malaria infections by integrating the age
profiles (from age 0 to 100 years) at each point in time, allowing
us to understand the intervention induced disturbance over the
time dynamics of malaria infections (both clinical and asymptom-
atic). As suggested by panels A and B, the overall impact of IPTc
should be greater in intermediate transmission areas (Figure 5C)
than in high transmission ones (Figure 5D). Figure 5C shows how
protection against malarial infections is expected to be sustained
for more than 3 years following a one year IPTc program (red
line). However, this comes at the expense of a small increase in the
number of clinical episodes (blue line). In high transmission
regions, IPTc exerts a small pressure on the overall dynamics and
the pre-intervention scenario is foressen to be restored in the year
following intervention conclusion (Figure 5D).
We also simulated the study conducted in Senegal by Cisse et al
[34], by using the adopted intervention schedule and calibrating the
force of infection according to the observed pre-intervention parasite
prevalence (Figure 6A,C). The procedure is replicated for a higher
Table 3. Intervention impact below 10 years of age, for different values of c and s, under intermediate transmission.
c Probability of clinical immunity acquisition
0 0.25 0.5 0.75 1
s Reduced risk of infection 1 0.0104 0.0120 0.0135 0.0150 0.0164
0.75 0.0106 0.0119 0.0131 0.0144 0.0156
0.5 0.0108 0.0118 0.0128 0.0138 0.0148
0.25 0.0110 0.0117 0.0124 0.0132 0.0139
0 0.0111 0.0116 0.0121 0.0126 0.0130
doi:10.1371/journal.pone.0006627.t003
Figure 4. Intervention impact on clinical malaria and overall
parasite prevalence. (A) IPTi impact on clinical malaria, assuming
several values for intervention coverage, as specified in the figure
legend. (B) Time dynamics of the proportion of people infected with
malaria, assuming different IPTi coverage rates as in (A).
doi:10.1371/journal.pone.0006627.g004
Figure 3. Targeted interventions according to endemic level.
The IPTi intervention outcome (red line) is compared with a population
without intervention in equilibrium conditions (black line), and a
tailored schedule for the administration of anti-malarial drugs (blue
line). These simulations are performed for a high transmission
transmission setting.
doi:10.1371/journal.pone.0006627.g003
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same general results as those found in Figure 5, the difference being
that the impact of IPTc on overall malaria transmission is at a smaller
scale in the Senegalese study. The difference advents from the
broader age range covered by IPTc in the Kenyan study [19].
In Figure 7A,C and 7B,D, we explore the effect of seasonality
on the IPTc interventions performed in Kenya [19] (previously
assessed in Figure 5) and Senegal [34] (previously assessed in
Figure 6), respectively. This first exploration suggests that the effect
of seasonality is quantitative, while the qualitative results remain
unchanged. In Figure A,B, the model predictions indicate a very
effective impact of IPTc over the clinical age profiles immediately
after administration of a course of drugs, and an increase in risk
following treatment. This qualitative behaviour is maintained
regardless of the age range covered by IPTc, seasonal fluctuations
in transmission, and transmission intensity. Again, we expect a
more pronounced impact on malaria transmission in the Kenyan
study, which encompasses a larger age range under prophylaxis.
Although the time dynamics in Figures 5C and 6C are a good
approximation for the average behaviour of what is observed in
Figure 7C,D, this should be regarded as an initial insight and the
study should be followed by a systematic analysis of varying
intervention schedules. In particular, when the dynamics occurs
near elimination thresholds, seasonality may be instrumental.
Table 4. IPTi impact below 10 years of age, in a high
transmission region, under different intervention coverage.
IPTi coverage
Impact ,1y r
of age
Impact .1y r
of age Overall impact
0.9 0.1998 20.0869 0.0557
0.75 0.1697 20.0730 0.0477
0.5 0.1164 20.0494 0.0331
0.25 0.0597 20.0250 0.0171
doi:10.1371/journal.pone.0006627.t004
Figure 5. Impact of an IPTc strategy apllied in 5 to 18 years old children on clinical malaria age profiles, and over time. Age profiles of
populations under an IPTc intervention calibrated from data in Clarke et al. [19] are compared with populations without intervention, represented by
black lines. (A) Clinical malaria age profiles, retrieved immediately after the third dose of treatment (blue line), and 4 months after the administration
of that course of drug (red line). (B) Represents the same as (A), but for a high transmission setting. (C), (D) Time dynamics of IPTc impact over all age
classes in mild and intense malaria transmission areas, respectively. Intervention (starting in year 1) shapes the dynamics of both clinical (blue line)
and asymptomatic/mild (red line) malaria. The dashed lines represent unperturbed equilibria.
doi:10.1371/journal.pone.0006627.g005
IPT Impact on Clinical Malaria
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design of intervention schedules tailored to specific regions. A
systematic analysis of this aspect is too extensive to be included in
the present study.
Discussion
Intermittent preventive treatment (IPT) is a very promising
approach to the management of clinical malaria burden in infants
and children. However, concerns as to whether immunity is being
allowed to build up during treatment, or if disease risk is actually
just being postponed to later ages (rebound effect), persist.
Although it is well established that parasites are rapidly cleared from
the bloodstream after administration of anti-malarial drugs [29,30],
reports on the prophylactic effect of SP (drug of choice for both IPTc
and IPTi) against a new infection refer mainly to malaria in pregnancy
[35–37], pointing to a 30% to 60% reduced risk of infection. While
data on howprophylaxis affects the probabilityoffunctional acquisition
of immunity are inconclusive, this can be explored using mathematical
models. To investigate the chances of immunity build up in individuals
who have received a drug dose, we introduce to out model parameter,
c, representing the probability of clinical immunity acquisition.
In the ideal scenario, where immunity is allowed to build up
during treatment as efficiently as if the individual goes through a full
length of infection (c=1), and the risk of infection is not reduced by
treatment (s=1), the modelled rebound effect is minimised. If
immunity is not built up efficiently (c,1), the proportion of
individuals still susceptible to clinical malaria after the last dose of
prophylactics may be large, thus, causing a rebound effect in later
ages. If the risk of infection is reduced by treatment (s,1), boosting
of immunity is lessfrequent and there is a greater risk of returning to
the non-immune compartment. Intervention outcomes in ages
following the last drug dose schedule are highly dependent on
transmissionlevelsandonhowtreatmentaffectsinfectiondynamics,
mainly the time for which the drug effect lasts, the drug induced
decreased risk of acquiring an infection, and the ability to acquire
functional clinical immunity while treated.
The model then suggests that the greater the risk of acquiring an
infection while treated, and the more that infection resembles a
natural one (in terms of inducing clinical immunity), the better the
outcome of intervention in terms of effectiveness is, during both
treatment and follow-up periods. Even when there is a noticeable
rebound effect (such as when c=0and s~0), the benefits of
implementing IPTi in infants are predicted to surpass the
drawbacks of having more cases in older children (Tables 2, 3).
This has been proposed by previous modelling studies [25,26].
The simulated dynamics of age dependent efficacy of IPTi
interventions are qualitatively equivalent in high transmission and
Figure 6. Impact of an IPTc strategy applied in 2 months to 5 years old children on clinical malaria age profiles, and over time. The
same as in Figure 5 but calibrated according to Cisse et al [34].
doi:10.1371/journal.pone.0006627.g006
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high transmission areas, incidence of clinical malaria is higher in
young children [9–11] and pregnant women [12]. In these regions,
the ages at which clinical malaria peaks coincide with the interval at
which interventions are being made, which translates into a great
effectiveness of intervention, although rebound may be present
(Figure 2B). The model predicts that the number of cases prevented
by intervening is greater than the excess of cases after intervention,
giving anoverall impact in clinical cases (acrossall age classes) ranging
from 0.4% to 6.8%. In intermediate transmission areas, where
occurrence of clinical cases is frequent in later ages [38], and where
the average age at infection is much higher than the age at which
prophylaxis is administered, the overall benefits of IPTi are almost
negligible, and the rebound effect is not significant either (Figure 2D).
The first year of age represents a small fraction of the cases of clinical
malaria, which implies that an intervention such as IPTi has a small
impact. The same relationship between transmission intensity and
IPTi efficacy has been noted in [25].
Furthermore, we notice that, although administration of IPTi
along with the EPI schedule facilitates logistics, the results using
this schedule are far from being optimal in every region. To
maximise the number of cases prevented by intervention at each
age, the schedule of intervention should be tailored to each region
according to their specific transmission levels. In intermediate
transmission areas, IPTi should be most effective if the schedule is
extended into early childhood. In high transmission regions a
tailored schedule very similar to EPI may be responsible for the
prevention of 2.7% more cases when compared to the typical IPTi
schedule.
The relationship between endemicity and intervention efficacy
is opposite when comparing IPTi and IPTc. Intermediate
transmission regions are highly sensitive to IPTc, in contrast to
the robustness of high transmission regions. Since intervention
affects children and toddlers, the age range under treatment
coincides with an age of high risk of acquisition of malaria when
transmission is low to moderate. Our results suggest that IPTc has
Figure 7. IPTc impact in seasonal settings. We mimic two studies conducted in regions with different seasonal transmission patterns [19,34]. (A)
Clinical malaria age profiles, immediately after the administration of the third dose of treatment (blue line), and 4 months after that (red line), for the
study in [19]. The dashed lines represent the age profiles retrieved under no treatment, for each of the mentioned times points. Differences in the
dashed lines refer to oscillations in transmission from one time point to the other. Intervention impact is measured as the difference between dashed
and full lines of the same color (C) Time dynamics of clinical (blue line) and asymptomatic malaria (red line) in a population in which IPTc was
implemented beginning in year 1 (full lines), following the schedule in [19], and in a population under no treatment (dashed lines). Replicating (A)
and (C), whilst using the characteristics of IPTc implementation in [34] and the seasonal transmission fluctuations in [42], we get (B) and (D),
respectively.
doi:10.1371/journal.pone.0006627.g007
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period in intermediate transmission areas, as reflected by the
reduction in clinical cases, and more significantly by the large
decrease in asymptomatic cases. A rebound of marginal magnitude
in clinical cases is expected to occur less than one year after the last
dose of SP.
Since IPTc intervention is discrete in time, it allows for a period
of time between doses when individuals are not protected by
prophylaxis, since SP is cleared from the blood stream in about
one month. The large age range tested in [19] and simulated here
ensures that efficacy is maximised, and the four month hiatus
between courses of drugs ensures minimal rebound, since clinical
immunity can be boosted by natural infections during this period.
The study in [34], while affecting a smaller age range comprised of
lower ages, used a monthly schedule of drug administration for a
period of 3 months. This schedule is particularly efficient in
tackling the clinical malaria burden in areas where transmission
mainly occurs in a short period of the year. If transmission is
sustained for a longer period, the time interval between doses
should be increased.
IPT interventions revolve around the idea of simultaneously
reducing the frequency of infection and life-threatening illness in
infants or children, while allowing immunity to build up. We
varied intervention coverage to explore the impact of IPTi on
malaria transmission in a highly endemic region. Our model finds
that high coverage has better results as to what concerns overall
parasite prevalence, although the actual reduction in the
proportion of infectious people is minimal. This contrasts with
the effects IPTc displays over parasite prevalence. The model
suggests that IPTc is more effective than IPTi in reducing the
number of malaria cases, particularly in intermediate transmission
areas.
Here we present a simplistic description of malaria transmission
that does not encompass features such as heterogeneity (both at the
level of host contact patterns and susceptibility) and stochasticity.
Rather, we focus on the essential mechanisms which characterise
malaria transmission on a population of individuals which exhibit
identical behaviour. More detailed models which also simulate
IPTi interventions [25], while discriminating transmission pro-
cesses at the individual level and allowing for stochasticity, have
obtained results which are strikingly similar to those presented
here. Indeed, stochasticity is only a concern when dealing with
very small numbers, such as in elimination scenarios. We
recognise, however, that the introduction of heterogeneity and
superinfection should increase the prevalence observed in the
model, inducing some resistance to perturbations in transmission.
The baseline transmission model presented here was fully
parameterised using datasets from several Sub-Saharan settings,
encompassing a broad range of transmission intensities, and its
parameters were subject to an extensive sensitivity analysis in [27].
The parameters defining the pharmacokinetics and pharmacody-
namics are fairly well understood [29–31]. What is not known,
however, is how drug dynamics and kinetics affect inherent
immune and transmission processes. The rate at which drug
effectiveness wanes is crucial in determining the extent of both
protection against clinical episodes during the first year of life, and
duration of rebound effect. Long lasting drugs confer extra efficacy
to IPT strategies, although rebound becomes much more
significant. IPT should also use a different combination of drugs
compared with what is used for treatment of clinical cases, in order
to minimize drug resistance issues. The exact value for the
parameter defining how immunity wanes in treated classes is
unknown. This parameter, however, has a small role to play, since
the rate at which the drugs are cleared from the bloodstream is
much faster than the rate of loss of clinical immunity.
Implementation of large scale therapeutic interventions must be
accompanied by careful assessment of the existing levels of drug
resistance. IPTi yields very little impact on the overall transmission
of malaria in endemic regions and is, therefore, unlikely to affect
the spread of drug resistance. The situation is less straightforward
for IPTc. Since this strategy is able to disturb malaria transmission
to some extent, it is more likely to influence the dissemination of
drug resistance, an aspect that deserves careful investigation.
Careful evaluation of the transmission characteristics of the
areas under study can be extremely useful in deciding which
program will be the most beneficial for each specific region. It has
been observed that P. falciparum transmission is decreasing in
some settings in sub-Saharan Africa [39,40]. Under circumstances
of falling malaria incidence, IPTi might become less efficacious
and IPTc might be a good strategy to consider. Synergies between
these and other control measures can also have a critical
importance in determining the potential impact of an integrated
intervention. This is particularly importance since interventions
integrating preventative methods may overcome the rebounds
predicted for single-intervention strategies [41]. These might be
especially useful not only for malaria control but also for end phase
elimination scenarios, where IPTc seems to be a good candidate as
a resurgence precluding strategy, due to its transmission lowering
potential.
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